Abstract:Abstract Background: Activating mutations in PIK3CA are frequent in breast cancer (Campbell et al. Cancer Res 2004;64:7678-7681). Previous analyses suggest that the presence of PIK3CA activating mutations were associated with poor clinical outcome (Li et al. Breast Can Res Treat 2006;96:91-95) and could confer resistance to treatment with trastuzumab (T) (Berns et al. Cancer Cell 2007;12:395-402). Lapatinib (L) is an oral tyrosine kinase inhibitor targeting EGFR and HER2 pathways. L plus capecitabine (C) has demonstrated efficacy in women with HER2+ metastatic breast cancer (MBC) previously treated with T (Geyer et al. N Engl J Med 2006;355(26):2733-2743). EGF109491 evaluated the efficacy of L+C in 52 Chinese HER2+ MBC patients. The clinical benefit rate (CBR) was 57.7% (PR 44% and SD 44%) and median progression free survival (PFS) was 6.3 months. The purpose of this analysis was to establish the frequency of PIK3CA mutations in this small cohort of Chinese patients and to determine if the presence of a PIK3CA mutation has any impact on clinical benefit to L+C.Methods: 38/52 patients provided tumor samples for biomarker analysis. Briefly, DNA was extracted from these tumor samples, amplified by PCR and sequenced by Pyrosequencing methods to identify the presence of frequent activating mutations in exons 9 and 20 in PIK3CA. Mutation status was tested for association with CBR and PFS using contingency table analysis and proportional hazards analysis respectively.Results:11/38 (29%) patients harbored a mutation in the PIK3CA gene, consistent with published frequencies. 9/11 mutations reside in the catalytic domain and 2/11 mutations reside in the accessory domain of the gene. There was no statistical association with CBR (p=0.639) or PFS (HR=1.01, p=0.989) in PIK3CA wildtype patients vs. PIK3CA mutant patients. PIK3CA wildtype n=27 (%)PIK3CA Mutation n=11 (%)CR0 (0)0 (0)PR12 (44%)4 (36%)SD13 (48%)5 (45%)PD1 (4%)1 (9%)Unknown1 (4%)1 (9%)HR1.01 (p=0.989) Conclusion: The frequency of PIK3CA mutations in this small cohort of Chinese HER2+ MBC patients is consistent with published frequencies. There was no statistically significant association between the presence of a PIK3CA mutation and clinical benefit to L+C in these patients. These results are in agreement with previous reports that mutations in PIK3CA do not seem to impact clinical outcome following L-containing treatment regimens. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1140.

Pik3ca Mutation Analysis in Chinese Patients with Solid Tumors.

P1.02-045 PIK3CA Mutations in Chinese Patients with Non-Small-Cell Lung Cancer

Clinicopathological Characteristics and Prognostic Analysis of PIK3CA Mutation in Breast Cancer Patients in Northwest China

Low Frequency of PIK3CA Gene Mutations in Hepatocellular Carcinoma in Chinese Population.

Frequency, Characterization, and Prognostic Analysis of PIK3CA Gene Mutations in Chinese Esophageal Squamous Cell Carcinoma.

KRAS, BRAF and PIK3CA Mutations and the Loss of PTEN Expression in Chinese Patients with Colorectal Cancer.

PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer

PIK3CA Mutation in Chinese Patients with Lung Squamous Cell Carcinoma

Frequency of Pik3ca Mutations in Chinese Her2+Metastatic Breast Cancer Patients and Association with Clinical Benefit to Lapatinib and Capecitabine Treatment.

The Spectrum, Tendency and Predictive Value of PIK3CA Mutation in Chinese Colorectal Cancer Patients

Characterization of PIK3CA and PIK3R1 Somatic Mutations in Chinese Breast Cancer Patients

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.

Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.

PIK3CA Mutations Define Favorable Prognostic Biomarkers in Operable Breast Cancer: a Systematic Review and Meta-Analysis

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup

Plasma PIK 3 CA Ctdna Specific Mutation Detected by Next Generation Sequencing is Associated with Clinical Outcome in Advanced Breast Cancer

Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population

Mutational Landscape of AKT1/2/3 in Chinese Patients with Solid Tumors.

The Study of PIK3CA Hotspot Mutations and Co-Occurring with EGFR, KRAS, and TP53 Mutations in Non-Small Cell Lung Cancer

[A Study of the Relationship Between the Mutation of PIK3CA, PTEN and the Occurrence of Liver Metastasis of Colorectal Cancer: Survival Analysis].

Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‐BRCA data